Cidara Therapeutics (CDTX)
(Real Time Quote from BATS)
$13.05 USD
+0.63 (5.07%)
Updated May 31, 2024 11:06 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Earnings News For CDTX
-
Cidara Therapeutics: Q1 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Cidara Therapeutics: Q3 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Cidara Therapeutics: Q1 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
-
Cidara Therapeutics: Q4 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
-
Cidara Therapeutics: Q3 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
-
Cidara Therapeutics: Q2 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
-
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
-
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know
-
Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates
-
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates
-
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release